Unassociated Document
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
SEC File
Number: 000-32141
CUSIP
Number: 67060U 10 9
NOTIFICATION
OF LATE FILING
(Check
One):
|
o Form 10-K o
Form 20-F o
Form 11-K x
Form 10-Q o
Form 10-D o
Form N-SAR o
Form
N-CSR
|
For the Quarterly Period Ended September 30,
2009
o Transition Report
on Form 10-K
o Transition Report
on Form 20-F
o Transition Report
on Form 11-K
o Transition Report
on Form 10-Q
o Transition Report
on Form N-SAR
For the Transition Period Ended:
_____________________
Read Instruction (on back page) Before
Preparing Form. Please Print or Type.
Nothing
in this form shall be construed to imply that the Commission has verified any
information contained herein.
If the
notification relates to a portion of the filing checked above, identify the
Item(s) to which the notification relates:
PART
I - REGISTRANT INFORMATION
Nutra
Pharma Corp.
Full Name
of Registrant
Former
Name if Applicable
1537 NW
65th
Ave
Address
of Principal Executive Office (Street and
Number)
Plantation,
FL 33313
City,
State and Zip Code
PART
II - RULES 12b-25(b) AND (c)
If the
subject report could not be filed without unreasonable effort or expense and the
registrant seeks relief pursuant to Rule 12b-25(b), the following should be
completed. (Check box if appropriate)
|
(a) The reason described in
reasonable detail in Part III of this form could not be eliminated without
unreasonable effort orexpense.
|
|
|
x |
(b) The subject
annual report, semi-annual report, transition report on Form 10-K, Form
20-F, Form 11-K, Form N-SAR orForm N-CSR, or portion thereof, will be
filed on or before the fifteenth calendar day following the prescribed due
date; orthe subject quarterly report or transition report on Form 10-Q or
subject distribution report on Form 10-D, or portion thereof, will be
filed on or before the fifth calendar day following the prescribed due
date; and |
|
|
|
(c) The accountant's
statement or other exhibit required by Rule 12b-25(c) has been attached if
applicable. |
PART III -
NARRATIVE
State
below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, 10-D,
N-SAR, N-CSR, or the transition report or portion thereof, could not be filed
within the prescribed time period.
The
Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2009
cannot be filed within the prescribed time period because the Company requires
additional time for compilation and review to ensure adequate disclosure of
certain information required to be included in the Form 10-Q. The
Company's Quarterly Report on Form 10-Q will be filed on or before the 5th
calendar day following the prescribed due date.
PART
IV - OTHER INFORMATION
(1) Name
and telephone number of person to contact in regard to this
notification
Rik
Deitsch
|
|
(954)
|
|
509-0911
|
(Name)
|
|
(Area
Code)
|
|
(Telephone
Number)
|
(2) Have
all other periodic reports required under Section 13 or 15(d) of the Securities
Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during
the preceding 12 months or for such shorter period that the registrant was
required to file such report(s) been filed? If the answer is no, identify
report(s).
x Yes o No
(3) Is it
anticipated that any significant change in results of operations from the
corresponding period for the last fiscal year will be reflected by the earnings
statements to be included in the subject report or portion thereof?
o Yes x No
If so,
attach an explanation of the anticipated change, both narratively and
quantitatively, and, if appropriate, state the reasons why a reasonable estimate
of the results cannot be made.
Nutra
Pharma Corp.
(Name
of Registrant as specified in Charter)
has
caused this notification to be signed on its behalf by the undersigned thereunto
duly authorized.
|
|
|
|
Date: November 17,
2009
|
By:
|
/s/ Rik
Deitsch |
|
|
Its: |
Chief
Executive Officer |
|
|
|
|
|
|
|
|
|